The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.
 
Tariqa Ackbarali
No Relationships to Disclose
 
Wendy Turell
No Relationships to Disclose
 
Elizabeth L. del Nido
No Relationships to Disclose
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Genomic Health; Immunomedics; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology; Seattle Genetics
 
Stephen V. Liu
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Genentech; Guardant Health; Inivata; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Pfizer; PharmaMar; Regeneron; Takeda
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Merus (Inst); Molecular Partners (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech